IBDEI2NF ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44453,1,3,0)
 ;;=3^Mesothelioma of Pleura
 ;;^UTILITY(U,$J,358.3,44453,1,4,0)
 ;;=4^C45.0
 ;;^UTILITY(U,$J,358.3,44453,2)
 ;;=^5001095
 ;;^UTILITY(U,$J,358.3,44454,0)
 ;;=C90.01^^200^2228^164
 ;;^UTILITY(U,$J,358.3,44454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44454,1,3,0)
 ;;=3^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,44454,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,44454,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,44455,0)
 ;;=C90.00^^200^2228^165
 ;;^UTILITY(U,$J,358.3,44455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44455,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,44455,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,44455,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,44456,0)
 ;;=C94.6^^200^2228^166
 ;;^UTILITY(U,$J,358.3,44456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44456,1,3,0)
 ;;=3^Myelodysplastic Disease NEC
 ;;^UTILITY(U,$J,358.3,44456,1,4,0)
 ;;=4^C94.6
 ;;^UTILITY(U,$J,358.3,44456,2)
 ;;=^5001846
 ;;^UTILITY(U,$J,358.3,44457,0)
 ;;=D61.82^^200^2228^167
 ;;^UTILITY(U,$J,358.3,44457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44457,1,3,0)
 ;;=3^Myelophthisis
 ;;^UTILITY(U,$J,358.3,44457,1,4,0)
 ;;=4^D61.82
 ;;^UTILITY(U,$J,358.3,44457,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,44458,0)
 ;;=D47.9^^200^2228^168
 ;;^UTILITY(U,$J,358.3,44458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44458,1,3,0)
 ;;=3^Neop Lymphoid,Hematopoietic & Related Tissue,Uncertain Behavior
 ;;^UTILITY(U,$J,358.3,44458,1,4,0)
 ;;=4^D47.9
 ;;^UTILITY(U,$J,358.3,44458,2)
 ;;=^5002260
 ;;^UTILITY(U,$J,358.3,44459,0)
 ;;=D53.9^^200^2228^172
 ;;^UTILITY(U,$J,358.3,44459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44459,1,3,0)
 ;;=3^Nutritional Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,44459,1,4,0)
 ;;=4^D53.9
 ;;^UTILITY(U,$J,358.3,44459,2)
 ;;=^5002298
 ;;^UTILITY(U,$J,358.3,44460,0)
 ;;=D47.4^^200^2228^173
 ;;^UTILITY(U,$J,358.3,44460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44460,1,3,0)
 ;;=3^Osteomyelofibrosis
 ;;^UTILITY(U,$J,358.3,44460,1,4,0)
 ;;=4^D47.4
 ;;^UTILITY(U,$J,358.3,44460,2)
 ;;=^5002259
 ;;^UTILITY(U,$J,358.3,44461,0)
 ;;=D59.1^^200^2228^27
 ;;^UTILITY(U,$J,358.3,44461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44461,1,3,0)
 ;;=3^Autoimmune Hemolytic Anemia,Other
 ;;^UTILITY(U,$J,358.3,44461,1,4,0)
 ;;=4^D59.1
 ;;^UTILITY(U,$J,358.3,44461,2)
 ;;=^5002324
 ;;^UTILITY(U,$J,358.3,44462,0)
 ;;=D51.3^^200^2228^187
 ;;^UTILITY(U,$J,358.3,44462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44462,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia,Other
 ;;^UTILITY(U,$J,358.3,44462,1,4,0)
 ;;=4^D51.3
 ;;^UTILITY(U,$J,358.3,44462,2)
 ;;=^5002287
 ;;^UTILITY(U,$J,358.3,44463,0)
 ;;=D77.^^200^2228^55
 ;;^UTILITY(U,$J,358.3,44463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44463,1,3,0)
 ;;=3^Disorder of Blood/Blood-Forming Organs in Diseases Classified Elsewhere,Other
 ;;^UTILITY(U,$J,358.3,44463,1,4,0)
 ;;=4^D77.
 ;;^UTILITY(U,$J,358.3,44463,2)
 ;;=^5002396
 ;;^UTILITY(U,$J,358.3,44464,0)
 ;;=D58.2^^200^2228^81
 ;;^UTILITY(U,$J,358.3,44464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44464,1,3,0)
 ;;=3^Hemoglobinopathies,Other
 ;;^UTILITY(U,$J,358.3,44464,1,4,0)
 ;;=4^D58.2
 ;;^UTILITY(U,$J,358.3,44464,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,44465,0)
 ;;=C88.8^^200^2228^101
 ;;^UTILITY(U,$J,358.3,44465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44465,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases,Other
 ;;^UTILITY(U,$J,358.3,44465,1,4,0)
 ;;=4^C88.8
 ;;^UTILITY(U,$J,358.3,44465,2)
 ;;=^5001750
 ;;^UTILITY(U,$J,358.3,44466,0)
 ;;=D70.8^^200^2228^170
